OPTIMAL phase III trial

PFS was significantly longer in erlotinib-treated Chinese patients with EGFR Mut+ NSCLC compared with that of patients treated with standard chemotherapy. Erlotinib was also better tolerated.1,2

Study design and endpoints1

  • OPTIMAL was a randomised phase III trial that took place across 22 centres in China. 
  • The trial compared erlotinib versus standard chemotherapy as first-line treatment for EGFR Mut+ NSCLC.


ECOG PS (Eastern Co-operative Oncology Group performance status)

Key Results


Patients receiving erlotinib had longer PFS than patients receiving chemotherapy.


Patients treated with erlotinib experienced fewer treatment related severe AEs, fewer grade 3/4 AEs and fewer dose reductions due to AEs than patients treated with chemotherapy.

Please click here for further safety data